Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   17/09/2025
144,87 USD (+0,83%)
(+0,83%)   17/09/2025
Grafiek Biogen Inc. Grafiek Biogen Inc.

Biogen Inc. in het nieuws

17 september 2025 · Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe · Persbericht

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status · Persbericht

3 september 2025 · Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status · Persbericht

2 september 2025 · /U P D A T E -- Eisai Inc./ · Persbericht

2 september 2025 · Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

29 augustus 2025 · FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease · Persbericht

25 augustus 2025 · Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress · Persbericht

25 augustus 2025 · Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab) · Persbericht

11 augustus 2025 · Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties